Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it will present data from the 2-year open-label study
(DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular
Dystrophy , one of the most common and devastating types of muscular
dystrophy. The findings indicate that Catena® slowed the decline in respiratory
function compared to the expected natural history in patients with Duchenne
Muscular Dystrophy. Data from this study are in agreement with and confirm data
from a randomized controlled study (DELPHI study) of 12 months duration . The
poster presentation will be given at the 16th International Congress of the
World Muscle Society in Almancil, Portugal on October 21, 2011.
Sharon is attending WMS 2011. PRAYING TO GOD to hear many good news on Duchenne from WMS 2011.
I wasn't able to attend the Santhera presentation (I had to leave before the last day) so I don't have this information--I can email the company to see if they can send us the data.
The abstract you posted included this statement: The change over time in respiratory as well as cardiac function data will be presented.
Can PPMD post those changes?